Site icon Asrar Qureshi’s Blogs

Medical Affairs Function in Pharmaceuticals – Asrar Qureshi’s Blog Post #873

Dear Colleagues!  This is Asrar Qureshi’s Blog Post #873 for Pharma Veterans. Pharma Veteransaims to share knowledge and wisdom from Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here.

Credit: Ivan Samkov

The Medical Affairs department within pharmaceutical companies is a critical component responsible for bridging the gap between the scientific aspects of the company’s products and the practical application of these products in healthcare settings. Their primary focus revolves around supporting and communicating the medical and scientific value of the company’s products to various stakeholders, including healthcare professionals, regulatory bodies, and internal teams. In some multinational pharmaceutical companies, even the marketing used to be under a medical director and was called medical marketing. Things have changed over time, and we shall discuss that also.

The rise of local pharma which is entirely based on generic medicines has changed the scenario in Pakistan significantly. Medical Affairs departments lost much of their value and visibility, or they were restricted to doing training of sales teams. It happened as the marketing became more and more commercial and selling focused on material benefits rather than clinical outcomes.

Here are some functions that medical affairs department should be assigned to handle.

Functions of Medical Affairs

Evolution of Medical Affairs

Internationally, the role of Medical Affairs has evolved significantly in recent years due to various factors.

Future of Medical Affairs

McKinsey has published an article in October 2023 titled ‘A vision for medical affairs 2030: Five priorities for patient impact’. It is a very significant article with very good information which I would like to discuss separately. Much of it may not be applicable to Pakistan Pharma Industry, but we shall see what is being considered in the pharma landscape internationally. The future trajectory of Medical Affairs in generic pharmaceutical companies should involve following key changes.

Overall, the future of Medical Affairs continues to evolve in response to advancements in technology, changing healthcare needs, and the demand for transparent, evidence-based medicine. Adaptability, innovation, and a patient-centric approach will be pivotal in shaping the future course of Medical Affairs in pharmaceutical companies.

Concluded.

Exit mobile version